International Clinical Psychopharmacology 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Predictors of rehospitalization in a naturalistic cohort of patients with bipolar affective disorder
There has only been limited research into the predictors of readmission in bipolar disorder. We carried out a 1-year follow-up of patients discharged from a single mental health unit following admission for treatment of an acute bipolar episode. Of 519 patients followed up for 1 year, 167 (32.2%) were readmitted. There was no association between readmission and any drug regimen. Prescription of antidepressants at discharge was not associated with increased risk of readmission [odds ratio (OR): 0.99, 95% confidence interval (CI): 0.98–1.01]. Among demographic factors, only smoking (OR: 1.75, 95% CI: 1.14–2.75) and age r...
Source: International Clinical Psychopharmacology - March 30, 2017 Category: Psychiatry Tags: Original Articles Source Type: research
A double-blind, placebo-controlled study of inositol in trichotillomania
Trichotillomania is characterized by repetitive pulling that causes noticeable hair loss. Data on the pharmacological treatment of trichotillomania are limited, with no clear first-line agent. The aim of the current study was to determine the efficacy and tolerability of inositol in adults with trichotillomania. A total of 38 individuals (35 women; mean age: 28.9±11.4) with trichotillomania entered a 10-week, double-blind, placebo-controlled trial to evaluate the safety and efficacy of inositol (dosing ranging from 6 to 18 g/day). Patients were assessed using the Massachusetts General Hospital Hair Pulling Scale, the NI...
Source: International Clinical Psychopharmacology - January 27, 2017 Category: Psychiatry Tags: Original Articles Source Type: research
Adverse events in children and adolescents treated with quetiapine: an analysis of adverse drug reaction reports from the Danish Medicines Agency database
Quetiapine is a low-affinity dopamine D2 receptor antagonist, approved for the treatment of bipolar disorder and schizophrenia in children and adolescents by the Food and Drug Administration, but not by European Medicine Agency. Although knowledge of adverse drug reactions in children and adolescents is scarce, quetiapine is increasingly being used for youth in Denmark. The aim of this case study is to discuss adverse drug events (ADEs) spontaneously reported to the Danish Medicines Agency on quetiapine used in the pediatric population in relation to adversive drug reactions (ADRs) reported in the European Summary of Produ...
Source: International Clinical Psychopharmacology - January 27, 2017 Category: Psychiatry Tags: Original Articles Source Type: research
The impact of paliperidone palmitate long-acting injection on hospital admissions in a mental health setting
We screened 216 patients in a retrospective observational investigator-initiated study, of whom 45.37% patients (n=98) were retained after the inclusion criteria were applied. These patients had been prescribed paliperidone palmitate long-acting injection (PPLAI) with diagnoses of schizophrenia, schizoaffective disorder and bipolar affective disorder. We investigated whether PPLAI has an effect on the frequency and length of admissions to mental health inpatient units, the number of contacts with Crisis Resolution Home Treatment Teams (CRHTT) and frequency of home visits by the CRHTT per patient, over 6 years, split using ...
Source: International Clinical Psychopharmacology - January 27, 2017 Category: Psychiatry Tags: Original Articles Source Type: research
Simvastatin adjunct therapy for negative symptoms of schizophrenia: a randomized double-blind placebo-controlled trial
We investigated the effects of simvastatin adjunctive therapy on the negative symptoms of schizophrenia. In this double-blind trial, inpatients with chronic schizophrenia were clinically stabilized on a constant dose of risperidone for at least 4 weeks before the study and were then randomized to receive risperidone (4–6 mg/day) plus either simvastatin (40 mg/day) (n=33) or placebo (n=33) for 8 weeks. The Positive and Negative Syndrome Scale was used to measure the negative, positive, and general symptoms of schizophrenia at baseline and every 2 weeks. The Hamilton Depression Rating Scale and the Extrapyramidal Sympt...
Source: International Clinical Psychopharmacology - January 27, 2017 Category: Psychiatry Tags: Original Articles Source Type: research
Is cerebrovascular disease a silent condition in patients with chronic schizophrenia-related disorders?
Patients with chronic schizophrenia-related disorders are at a heightened risk of developing cardiovascular disease. The presence and interpretation of cerebral vascular lesions in neuroimaging tests in these patients represents a common clinical challenge. Nevertheless, the literature on cerebrovascular disease in this population is scarce and contradictory. The aim of this study was to analyse the relationship between schizophrenia-related disorders and cerebrovascular morbidity. A case–control study compared cerebrovascular morbidity in a group of patients with schizophrenia-related disorder versus a group of patients...
Source: International Clinical Psychopharmacology - January 27, 2017 Category: Psychiatry Tags: Original Articles Source Type: research
Effects of levomilnacipran extended-release on major depressive disorder patients with cognitive impairments: post-hoc analysis of a phase III study
Performance-based cognitive data were collected using the Cognitive Drug Research System in a study of levomilnacipran extended-release (ER) 40–120 mg/day (NCT01034462) in adults with major depressive disorder. These data were analyzed post-hoc to explore the relationship between cognitive measures, depression symptoms (Montgomery–Åsberg Depression Rating Scale, MADRS), and self-reported psychosocial functioning (Sheehan Disability Scale; SDS). Changes from baseline were analyzed in the intent-to-treat population and subgroups with impaired attention, as indicated by baseline Cognitive Drug Research System scores fo...
Source: International Clinical Psychopharmacology - January 27, 2017 Category: Psychiatry Tags: Original Articles Source Type: research
Patients on psychotropic medications and herbal supplement combinations: clinical considerations
Populations using herbs and herbal preparations are widespread and growing. As many herbal ingredients exert actions on psychotropic drug targets, psychiatrists should be well informed and aware of potential drug–drug interactions in clinical practice. Reliable and clinically useful information in this area, however, is fragmented, if not deficient. This paper reviewed the clinical aspects of herb–drug interactions, focusing in particular on the monoamine oxidase enzyme and P450 cytochrome enzyme-inhibitory properties of herbs and their potential interference with psychotropic drug actions and clinical judgement. (Sour...
Source: International Clinical Psychopharmacology - January 27, 2017 Category: Psychiatry Tags: Review Articles Source Type: research
Lithium and cognition in those with bipolar disorder
Although a percentage of patients report cognitive side-effects when taking lithium, it can be difficult to determine from the literature whether any cognitive changes reflect lithium itself, the lithium serum level, residual mood symptoms, the underlying nature of bipolar disorder, or biological alterations such as hypothyroidism. This review was carried out to synthesize and evaluate relevant literature examining any cognitive impact of lithium in those with bipolar disorder. The effect of lithium in those with bipolar disorder was examined across the cognitive domains of attention, psychomotor speed, processing speed, w...
Source: International Clinical Psychopharmacology - January 27, 2017 Category: Psychiatry Tags: Review Articles Source Type: research
Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia: Erratum
No abstract available (Source: International Clinical Psychopharmacology)
Source: International Clinical Psychopharmacology - December 2, 2016 Category: Psychiatry Tags: Erratum Source Type: research
Pregabalin for generalized anxiety disorder: an updated systematic review and meta-analysis
Generalized anxiety disorder (GAD), characterized by pervasive and highly distressing anxiety and worries, is associated with severe impairment. Although numerous agents from various drug classes are available to treat GAD, as many as 50% of patients have inadequate response, constituting an important medical frontier. In the face of this challenge, new pharmacological alternatives need to be further studied aiming at clinical improvement and better quality of life for patients. To assess the efficacy of pregabalin (PGB) compared with placebo for amelioration of anxiety symptoms in patients with GAD. A systematic literatur...
Source: International Clinical Psychopharmacology - December 2, 2016 Category: Psychiatry Tags: Review Article Source Type: research
Early improvement with pregabalin predicts endpoint response in patients with generalized anxiety disorder: an integrated and predictive data analysis
Generalized anxiety disorder (GAD), a common mental disorder, has several treatment options including pregabalin. Not all patients respond to treatment; quickly determining which patients will respond is an important treatment goal. Patient-level data were pooled from nine phase II and III randomized, double-blind, short-term, placebo-controlled trials of pregabalin for the treatment of GAD. Efficacy outcomes included the change from baseline in the Hamilton Anxiety Scale (HAM-A) total score and psychic and somatic subscales. Predictive modelling assessed baseline characteristics and early clinical responses to determine t...
Source: International Clinical Psychopharmacology - December 2, 2016 Category: Psychiatry Tags: Original Articles Source Type: research
Psychological dependence on antidepressants in patients with panic disorder: a cross-sectional study
This study was carried out in four psychiatric clinics in Tokyo, Japan. Individuals were eligible if they were outpatients aged 18 years or older and fulfilled the diagnostic criteria for panic disorder (ICD-10). Assessments included the Japanese Versions of the Severity of Dependence Scale (SDS), the Self-Report Version of Panic Disorder Severity Scale (PDSS-SR), and the Quick Inventory of Depressive Symptomatology-Self Report. Eighty-four individuals were included; of these, 30 patients (35.7%) showed psychological dependence on antidepressants (i.e. a total score of ≥5 in the SDS). A multiple regression analysis showe...
Source: International Clinical Psychopharmacology - December 2, 2016 Category: Psychiatry Tags: Original Articles Source Type: research
Effects of vilazodone on sexual functioning in healthy adults: results from a randomized, double-blind, placebo-controlled, and active-controlled study
The aim of this study is to evaluate the effects of vilazodone on sexual functioning in healthy, sexually active adults and assess the impact of medication nonadherence in this type of trial. Participants were randomized to vilazodone (20 or 40 mg/day), paroxetine (20 mg/day), or placebo for 5 weeks of double-blind treatment. The primary endpoint was change from baseline to day 35 in Change in Sexual Functioning Questionnaire (CSFQ) total score in the intent-to-treat (ITT) population. Post-hoc analyses were carried out in modified intent-to-treat (mITT) populations that excluded participants in the active-treatment gro...
Source: International Clinical Psychopharmacology - December 2, 2016 Category: Psychiatry Tags: Original Articles Source Type: research
Pharmacokinetics and effect on the corrected QT interval of single-dose escitalopram in healthy elderly compared with younger adults
In conclusion, the pharmacokinetics and QT effect of a single dose of escitalopram observed in the elderly without comorbidities and younger adults were generally similar. (Source: International Clinical Psychopharmacology)
Source: International Clinical Psychopharmacology - December 2, 2016 Category: Psychiatry Tags: Original Articles Source Type: research
